Auren Rx Review: A Real Monthly Rung, an Unpublished Map

Auren Rx (aurenrx.com) sells ten prescription products and prices all of them the same way: a discounted subscribe rung and, beside it, an explicit "monthly, no commitment" rung. In a batch of seven telehealth sellers screened together in August 2026 it produced the most complete ladder of the seven — and the single largest disclosure gap. Both of those are structural, and a reader should weigh them together.

Two rungs on everything

Standard semaglutide is $199 a month with no commitment, or $169 on a subscription. Standard tirzepatide is $299 with no commitment, or $259 subscribed. There is a separate microdose program: semaglutide at $149 monthly or $129 subscribed, tirzepatide at $250 monthly or $229 subscribed.¹

We file the no-commitment figures. That is not a stylistic choice. Auren Rx's own structured data emits the subscribe rung as its offer price, which means every automated shopping surface and price aggregator that reads the page will record $169 and $259 rather than $199 and $299. If you have seen Auren Rx quoted somewhere cheaper than this review quotes it, that is almost certainly why.

There is no prepay tier at all, so there is no prepay-as-monthly trap. Billing is disclosed as approximately every 28 to 30 days — slightly short of a calendar month, and stated rather than hidden, which is a meaningful difference from Vyvron's undisclosed four-week cycle. He & She MD does the opposite on its hormone line, publishing a full four-term ladder for GLP-1 and no price at all for estradiol or progesterone. Cancellation is month-to-month, and a membership can be paused with no further charge until you order a refill. On the other side of that disclosure question sits a program that bills monthly with no minimum term and still will not show you a figure until the medical questionnaire is done, which is a reminder that flexible billing and legible pricing are separate virtues.

The selector that starts on the wrong molecule

The weight-loss page loads with its molecule selector already set to tirzepatide. If you open it, glance at the price, and leave, you have recorded tirzepatide's number under semaglutide's name — a $100 error in the direction that makes the program look expensive, and the mirror-image error is just as easy to make on a page configured the other way. Check which molecule is selected before you write anything down. Our semaglutide versus tirzepatide guide covers why the two prices differ in the first place.

The navigation carries a related trap. It reads "semaglutide and tirzepatide from $129/mo", and $129 is the microdose semaglutide subscribe rung. The cheapest standard GLP-1 rung is $169 subscribed, or $199 monthly. The figure is real; the heading it sits under is not the product it belongs to.

The microdose program is a real program

Unlike most operators that sell "microdosing" as a marketing label over the same vial, Auren Rx runs it as a separate program with its own page, its own intake and its own four-rung price table across both molecules. For a reader starting low to see whether the insulin signal moves before committing to a full titration, that is the structure you want — a published price for the low-dose product rather than the full-dose price with a smaller number written on it. The mechanism is set out in our guide to insulin resistance and GLP-1 medicines.

The rest of the ladder

NAD+ is priced across seven rungs and three routes: injection at $209 a month; nasal spray at $169 or $219 for 15 and 30 mL at 100 mg/mL, and $189 or $249 at 300 mg/mL; cream at $155 for 30 g and $215 for 90 g. Sermorelin is $199. Glutathione is $119 injected and $109 nasal. GHK-Cu cream is $109, tretinoin $49, oral minoxidil $49, valacyclovir $39 or $49, and estradiol $89 or $99 as a patch and $69 or $79 as a tablet.¹ All figures are the no-commitment rungs. Two of those products are missing from the site's own sitemap, which is worth knowing if you are trying to establish what a company sells by crawling it.

What is not published

Auren Rx never says which states it serves. Its terms refer to "certain states" and to "a state where we operate", and no list exists anywhere on the site. Every other provider in this batch publishes something — a list, a count, an exclusion. This one publishes nothing, and it is the first question to put to them, since a program's answer determines whether the rest of the review is relevant to you at all. Our checklist for judging a program before you pay treats state disclosure as a threshold item rather than a detail.

The clinical layer is Beluga Health, P.A., a real telehealth professional association, but no individual prescriber is named and no NPI is published, so nothing can be checked against the national registry the way The Edit's medical director can be. The dispensing pharmacy is never named individually — the site refers to its own pharmacy network, and notes that patients may elect a local pharmacy instead, in which case the membership fee excludes the medication cost. The legal entity is Hades Capital LLC, doing business as Auren RX, with no address published.

The membership fee is charged the day membership commences and is non-refundable once paid. The redeeming detail is the sequence: membership begins after a provider communicates a care plan and you elect to proceed, so it follows clinical review rather than preceding it. That is the right way round, and it is rarer in this batch than it should be.

Product pages show star ratings between 4.6 and 4.9 with no review count and no source. We are not repeating them.

The FDA screen

We queried the FDA's live warning-letter index in August 2026 for the brand in several spellings, for its legal entity, for its medical group and for its intake platform. Nothing matched in the company column.² The pass carried a positive control — an unrelated telehealth seller with a real 2026 letter — which returned correctly every time, so the zero is a clean record rather than a broken query.

Where it lands

Judged on the three things that decide whether treatment for insulin resistance is sustainable — supply that keeps arriving, a dose you can climb without a repricing, and an exit that costs nothing — Auren Rx answers all three in published writing, which puts it near the top of this batch. Then it declines to say where it operates, which for some readers makes the rest academic. Read it against the rubric on our Luna Fit Score methodology page. Auren Rx is not scored there: it is not in our ranking, we earn nothing from it, and this review exists because a complete price ladder deserves to be reported accurately, including the part the company left blank.